REGN Stock Recent News

Regeneron CEO Leonard Schleifer on Tuesday said that Health and Human Services Secretary Robert F. Kennedy Jr.

Regeneron founder, chair and CEO Leonard Schleifer joins 'Squawk Box' to discuss the impact of President Trump's tariff policies on biotech and pharmaceuticals, his thoughts on HHS Secretary RFK Jr., fixing the health care industry, and more.

ALC, GKOS and REGN are well-positioned to benefit from the evolving space of cell-based ophthalmic therapy.

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for COPD in more than a decade in Japan and the sixth approved indication for chronic diseases with underlying type 2 inflammation Paris and Tarrytown, NY, March 28, 2025. The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in adults whose disease is not adequately controlled with existing therapy.

As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and negative news. Investors clearly took the latter more to heart, as they traded down a wide variety of stocks in both fields.

TARRYTOWN, N.Y., March 25, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2025 financial and operating results on Tuesday, April 29, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.

SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Shareholders Foundation, Inc. announced that a lawsuit is pending for certain investors in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Investors who purchased shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) prior to November 2023 and continue to hold any of those NASDAQ: REGN shares, should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Regeneron Pharmaceuticals, Inc. is a well-managed company with a diverse pipeline, but faces the likely decline in revenues from its key drug, Eylea. The loss of Eylea's patent protection has led to increased competition and pricing pressures, impacting the company's revenue and profit margins. Despite these challenges, Regeneron's other drugs, particularly Dupixent and Libtayo, show promise for future growth and revenue generation.

Although sometimes overshadowed by the all-important income statement, the balance sheet can offer essential insights into a company's financial health. It revolves around the balance between a company's assets and liabilities.